Tirzepatide (Zepbound) produces the most weight loss of any currently approved GLP-1-based medication, with an average of about 20% body weight reduction in clinical trials. That’s roughly 6.5 percentage points more than semaglutide (Wegovy), which itself outperforms the older daily injection liraglutide (Saxenda) by a wide margin. But “best” depends on more than raw numbers. Availability, side effects, insurance coverage, and your individual health profile all play a role.
How the Options Compare by Weight Loss
A head-to-head trial published in the New England Journal of Medicine settled the top-line question directly. At 72 weeks, people taking tirzepatide lost an average of 20.2% of their body weight, compared to 13.7% for those on semaglutide. That difference of 6.5 percentage points was statistically significant. For someone starting at 250 pounds, that’s roughly 50 pounds lost on tirzepatide versus 34 pounds on semaglutide.
In its standalone trial, tirzepatide at the highest dose (15 mg) showed a mean weight loss of 20.9% at 72 weeks. More striking: 57% of participants on the 10 mg or 15 mg doses lost 20% or more of their body weight, compared to just 3% on placebo.
Semaglutide’s landmark trial showed a 14.9% average weight reduction at 68 weeks versus 2.4% for placebo. That’s a substantial result on its own, and it made Wegovy a landmark drug when it launched. It simply gets outperformed by tirzepatide.
Liraglutide (Saxenda), the first GLP-1 approved for weight management, falls well behind both. In a direct comparison with semaglutide, liraglutide produced only 6.4% weight loss versus semaglutide’s 15.8%. Liraglutide also requires daily injections rather than weekly, making it less convenient.
Why Tirzepatide Works Differently
Tirzepatide isn’t purely a GLP-1 drug. It activates two gut hormone receptors instead of one: GLP-1 and GIP. This dual action appears to amplify the effects on appetite, blood sugar regulation, and how the body processes fat. Semaglutide and liraglutide target only the GLP-1 receptor. That difference in mechanism likely explains the gap in weight loss results, though researchers are still working out the precise reasons why adding GIP activation makes such a difference.
An Oral Option Is Available
For people who prefer not to inject, oral semaglutide at a 25 mg daily dose produced a 13.6% reduction in body weight at 64 weeks in a clinical trial, compared to 2.2% for placebo. That’s close to what injectable semaglutide delivers. The tradeoff is that oral semaglutide must be taken on an empty stomach with a small amount of water, and you need to wait at least 30 minutes before eating or drinking anything else. There is no oral form of tirzepatide currently available.
Side Effects Are Similar Across the Class
All GLP-1 medications cause gastrointestinal side effects, especially during the first weeks at each new dose level. The profiles for semaglutide and tirzepatide are broadly comparable, with some differences in specific symptoms.
- Nausea affects roughly 21.5% of semaglutide users and 25% of tirzepatide users.
- Diarrhea occurs in about 10.6% on semaglutide and 15% on tirzepatide.
- Vomiting rates are similar at around 9% for both.
- Reduced appetite is reported by about 5% on semaglutide and 10% on tirzepatide (though this is partly how the drugs work).
- Constipation is notably more common with semaglutide (around 8%) than tirzepatide (less than 1%).
These side effects are the main reason both drugs use a slow dose escalation schedule. You don’t start at the full dose. Semaglutide begins at 0.25 mg per week and increases every four weeks until reaching the target of 2.4 mg, a process that takes 16 to 20 weeks. Tirzepatide starts at 2.5 mg and goes up in 2.5 mg steps every four weeks toward a maximum of 15 mg. Many people find their side effects manageable at lower doses but hit a wall at higher ones, and studies show that a significant number of patients never reach the top maintenance dose.
Semaglutide Has Proven Heart Benefits
One area where semaglutide currently has an edge is cardiovascular data. In a trial of over 17,600 people with obesity and existing heart disease (but no diabetes), semaglutide reduced the risk of heart attack, stroke, or cardiovascular death by 20% over an average of 33 months. No comparable cardiovascular outcomes trial has been completed for tirzepatide yet. If you have heart disease or significant cardiovascular risk factors, this may factor into which medication your provider recommends.
Practical Factors That Affect Your Choice
The best GLP-1 medication on paper isn’t always the best one for a specific person. Several real-world factors matter just as much as clinical trial averages.
Insurance coverage varies widely. Some plans cover Wegovy but not Zepbound, or vice versa. Out-of-pocket costs for either drug run over $1,000 per month without coverage. Supply shortages have also affected both medications since their launch, though availability fluctuates. A drug you can actually get and afford will always outperform one you can’t.
Individual response varies too. Clinical trial averages don’t predict what any one person will lose. Some people on semaglutide lose more than the average tirzepatide user, and some people on tirzepatide lose less than the semaglutide average. If you’ve already tried one medication and hit a plateau or can’t tolerate the side effects, switching to the other is a reasonable conversation to have with your provider.
For people with type 2 diabetes alongside obesity, both drugs are available under different brand names (Mounjaro for tirzepatide, Ozempic for semaglutide) and at different doses. The weight loss in people with diabetes tends to be somewhat lower than in those without it, but the metabolic benefits of blood sugar control add another layer of value.